ABSTRACT
A 53-year-old woman with a history of psoriasis presented with severe cutaneous lesions associated with psoriasis. The woman was mentally handicapped; she was able to converse monosyllabically with her mother only and was very limited in social interactions. After preliminary investigations, a biological treatment was proposed. Etanercept was started in October 2006. The patient responded rapidly and, after 3 months, achieved a 75% improvement in the psoriasis area and severity index (PASI 75) score. Most notable, however, was that she began interacting with other people, even if they were not familiar to her. Subsequent cutaneous relapses were treated successfully with etanercept. Very few articles regarding etanercept and neurological or psychiatric problems are present in the literature. According to recent studies, etanercept could improve verbal fluency and cognitive and behavioural functions in Alzheimer's disease, so that we can suggest a potential role and use in neurological disorders.
Subject(s)
Immunoglobulin G/therapeutic use , Immunologic Factors/therapeutic use , Psoriasis/drug therapy , Receptors, Tumor Necrosis Factor/therapeutic use , Etanercept , Female , Follow-Up Studies , Humans , Middle Aged , Psoriasis/physiopathology , Recurrence , Severity of Illness Index , Treatment OutcomeABSTRACT
A 10-month-old child presented with an ulcerated lesion on his right arm. The lesion was caused by arginine monohydrochloride extravasation during growth hormone testing, performed 2 months before. On physical examination, there was a 3 cm x 4 cm oval sore, with a thick fibrous base and turgid, violaceous, raised edges on the dorsal aspect of the child's right hand and wrist. Conservative management with local medications led to complete resolution within 2 months.
